Quality of life and pruritus over 52 weeks of apremilast treatment in biologic-naive patients with moderate plaque psoriasis: Results of a real-world, multicenter, prospective study in Greece (APRAISAL)

被引：0
|
作者：
Ioannides, Dimitrios [1 ,2 ]
Tampouratzi, Eleftheria [3 ]
Rigopoulos, Dimitrios [4 ]
Drosos, Alexandros [5 ]
Rovithi, Evangelia [6 ]
Papadavid, Evangelia [7 ]
Papageorgiou, Marina [8 ]
Bassukas, Ioannis [9 ]
Zafiriou, Efterpi [10 ]
Panagakis, Pantelis [11 ]
机构：
[1] Aristotle Univ Thessaloniki, Univ Dept Dermatol 1, Thessaloniki, Greece
[2] Hosp Venereal Skin Dis Thessaloniki, Thessaloniki, Greece
[3] Piraeus Reg Gen Hosp Tzaneio, Dermatol Unit, Piraeus, Greece
[4] Natl Kapodistrian Univ Athens, Dept Dermatol & Venereol 1, Athens, Greece
[5] Gen Hosp Xanthi, Dept Dermatol, Athens, Greece
[6] Venizeleio Pananeio Gen Hosp Heraklion, Dept Dermatol & Venereol, Iraklion, Greece
[7] Natl Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Dept Dermatol & Venereol 2, Athens, Greece
[8] Hosp Venereal & Skin Dis Thessaloniki, State Dept Dermatol, Thessaloniki, Greece
[9] Univ Ioannina, Dept Skin & Venereal Dis, Ioannina, Greece
[10] Univ Gen Hosp Larissa, Univ Clin Dermatol, Larisa, Greece
[11] Andreas Sygros Hosp Athens, Dermatol & Venereol Dept NHS, Athens, Greece
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27506
引用
收藏
页码：AB150 / AB150
页数：1
相关论文
共 50 条
  • [21] Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis
    Armstrong, April
    Levi, Eugenia
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (12) : 1240 - 1245
  • [22] Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study
    Wollenhaupt, Jurgen
    Bach, Christian
    Roemmler-Zehrer, Josefine
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] Real-World Experience of Secukinumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis in Greece: 3-Year Interim Results of the SERENA Study
    Ioannides, Dimitrios
    Rigopoulos, Dimitrios
    Papakonstantis, Markos
    Chasapi, Vasiliki
    Deligiannis, Panagiotis
    Rigatos, Panagiotis
    Lefaki, Ioanna
    Papadavid, Evangelia
    Pokas, Eteoklis
    Tsilifis, Spyridon
    Roussaki-Schulze, Angeliki-Viktoria
    Barkis, Ioannis
    Lazaridou, Elisabeth
    Fotiadou, Christina
    Zisimou, Chrysa
    Kallidis, Panagiotis
    Chatzakis, Vasileios
    Oikonomou, Chrysa
    Madia, Xenia
    DERMATOLOGIC THERAPY, 2024, 2024
  • [24] Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study
    Ding, Yangfeng
    Li, Wei
    Guan, Xin
    Liu, Na
    Zhou, Ying
    Li, Gaojie
    Wang, Xiaohua
    Wang, Zhidong
    Xiao, Xiao
    Yang, Bin
    Lv, Chengzhi
    Zhang, Chunlei
    Shi, Yuling
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 1803 - 1814
  • [25] Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study
    Georgakopoulos, Jorge R.
    Ighani, Arvin
    Phung, Michelle
    Yeung, Jensen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 1019 - 1020
  • [26] Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
    Yeung, Jensen
    Sood, Siddhartha
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [27] Long-term real-world effectiveness of deucravacitinib in psoriasis: A 52-week prospective study stratified by prior apremilast or biologic therapy
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2025,
  • [28] Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics
    Mortato, E.
    Artosi, F.
    Borselli, C.
    Compagnucci, I.
    Rivieccio, Antonia
    Lanna, C.
    Lambiase, S.
    Gaeta Shumak, R.
    Loconsole, F.
    Bianchi, L.
    Campione, E.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
  • [29] Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study
    Colombo, Delia
    Bianchi, Luca
    Fabbrocini, Gabriella
    Corrao, Salvatore
    Offidani, Annamaria
    Stingeni, Luca
    Costanzo, Antonio
    Pellacani, Giovanni
    Peris, Ketty
    Bardazzi, Federico
    Argenziano, Giuseppe
    Ruffolo, Silvana
    Dapavo, Paolo
    Carrera, Carlo
    Fargnoli, Maria Concetta
    Parodi, Aurora
    Romanelli, Marco
    Malagoli, Piergiorgio
    Talamonti, Marina
    Megna, Matteo
    Raspanti, Massimo
    Paolinelli, Matteo
    Hansel, Katharina
    Narcisi, Alessandra
    Conti, Andrea
    De Simone, Clara
    Chessa, Marco Adriano
    De Rosa, Alina
    Provenzano, Eugenio
    Ortoncelli, Michela
    Moltrasio, Chiara
    Fidanza, Rosaria
    Burlando, Martina
    Tonini, Annalisa
    Gaiani, Francesca Maria
    Simoni, Lucia
    Ori, Alessandra
    Fiocchi, Martina
    Zagni, Emanuela
    DERMATOLOGIC THERAPY, 2022, 35 (01)
  • [30] Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
    Ruggiero, Angelo
    Fabbrocicni, Gabriella
    Cacciapuoti, Sara
    Potestio, Luca
    Gallo, Lucia
    Megna, Matteo
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 529 - 536
12345